Kiran Mazumdar-Shaw

Biotech pioneer's wealth climbed along with shares of her listed Biocon, which have more than doubled in the past year. The company, Asia's largest insulin producer, is aiming for a 10% share of the global market. In July it launched a disposable insulin pen in Japan with partner FUJIFILM Pharma, while in August biosimilar drugs to treat certain cancers, codeveloped with U.S.-based Mylan, were accepted by European regulators for review; news of these milestones lifted the stock. Shares of contract research arm Syngene are up 92% since its IPO in August 2015. <br> Mazumdar-Shaw was recently awarded the Chevalier de l'Ordre National de la Legion d'Honneur, France's highest civilian honor, for her outstanding contribution to bioscience